Orchestra BioMed Holdings, Inc. (OBIO)
After hours:
| Previous close | 4.8800 |
| Open | 4.9075 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.8200 - 4.9851 |
| 52-week range | 4.2200 - 20.1900 |
| Volume | |
| Avg. volume | 43,196 |
| Market cap | 177.143M |
| Beta (5Y monthly) | 0.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.33 |
GlobeNewswireOrchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
Patent estate covering atrioventricular interval modulation (“AVIM”) therapy includes 37 issued U.S. patents and 73 patents outside the U.S. that collectively comprise over 1,800 claims related to the treatment of hypertensionAVIM therapy is currently being studied in the BACKBEAT global pivotal study in collaboration with MedtronicOrchestra BioMed to provide detailed overview of AVIM therapy and the BACKBEAT global pivotal study in upcoming R&D day on June 11, 2024 in New York City NEW HOPE, Pa
- GlobeNewswire
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an in-person R&D day at the Lotte New York Palace Hotel on Tuesday, June 11, 2024 at 10:00 AM ET. To register, click here. The event will feature presentations by company management and key opinion leaders related to the Co
Simply Wall St.Orchestra BioMed Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Orchestra BioMed Holdings ( NASDAQ:OBIO ) Full Year 2023 Results Key Financial Results Net loss: US$49.1m (loss widened...
